Developer docs
API playgroundTry for free, no card

Search company profiles

Merz Pharma

Full company profile

uuid0006mhc

Namestring
Merz Pharma
Legal namestring
Merz Pharma GmbH & Co.KGaA
Websiteurl
merz.com
Company typeenum
Private
Founded yearint
1908
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersDeutsch, Germany
HQ citystring
Deutsch
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
aesthetic medicine products, botulinum toxin therapy, dermal filler treatments, neurological disorder treatments, consumer healthcare products
Industry2 codes
1Dermatology & Aesthetics Pharmaceuticals
CodeHLAIAAAKPrimaryYes
2Specialty Care Pharmaceuticals
CodeHLAIAAABPrimaryNo
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code4 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
  • Perfumes, Cosmetics & Other Toilet Preparations2844
Product category
Aesthetic Medicine and Pharmaceuticals
No data
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1Ultherapy PRIME
Description

FDA-cleared ultrasound treatment with real-time visualization for skin lifting

merz.com
+8 more records
Core offering1 text field

Merz Pharma is a diversified healthcare company that develops, manufactures, and markets aesthetic medicine products (neurotoxins like XEOMIN/Bocouture, dermal fillers like BELOTERO, and the Ultherapy PRIME ultrasound device for non-invasive skin lifting), neurological disorder therapeutics (XEOMIN for spasticity and sialorrhea), and consumer health and wellness products (tetesept, SOS, Zirkulin, Merz Spezial, Brooklyn Soap Company) through three business units: Merz Aesthetics, Merz Therapeutics, and Merz Lifecare.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Merz Pharma operates as a diversified healthcare company organized into three main business units: Merz Aesthetics (aesthetic medicine and skin rejuvenation products), Merz Therapeutics (neurological disorder treatments including botulinum toxin-based therapies like XEOMIN and Bocouture), and Merz Lifecare (consumer health brands including tetesept, SOS, Zirkulin, and Brooklyn Soap Company). The company also offers medical devices like Ultherapy PRIME for non-invasive skin lifting and BELOTERO dermal fillers. Founded in 1908 and headquartered in Frankfurt, Germany, Merz is a family-owned company celebrating over 110 years of operation.

Product and service7 records
1Merz Aesthetics
CategoryAesthetic medicine
2Merz Therapeutics
CategoryNeurological therapeutics
3Merz Lifecare
CategoryConsumer health and wellness
4Ultherapy PRIME
CategoryMedical device / aesthetic equipment
5BELOTERO
CategoryDermal filler / aesthetic medicine
6XEOMIN (incobotulinumtoxinA)
CategoryBotulinum toxin therapeutic
7Bocouture
CategoryNeurotoxin / aesthetic medicine
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Galderma
TypeDirect peer
Description

Pure-play dermatology company offering Restylane and Sculptra filler franchises plus a prescription skincare portfolio. Directly comparable to Merz Aesthetics in hyaluronic acid fillers and dermatology-focused product strategy, and a key competitor in physician-dispensed aesthetics channels.

2Revance Therapeutics
TypeEmerging player
Description

Aesthetics and therapeutics company with the RHA dermal filler line and the DaxibotulinumtoxinA neuromodulator programme. Overlaps with Merz Aesthetics across fillers and neurotoxins and with Merz Therapeutics in neurology pipeline development.

3Croma-Pharma
TypeEmerging player
Description

Austrian aesthetics company focused on hyaluronic acid fillers (Princess), botulinum toxin and PRP, plus ophthalmology. Overlaps with Merz Aesthetics' filler franchise and competes in similar medical-aesthetic distribution channels across Europe.

4Cynosure / Lutronic
TypeEmerging player
Description

Aesthetic energy-based device manufacturers offering laser, RF and ultrasound platforms. Compete with Merz's Ultherapy PRIME in non-invasive skin lifting/tightening and adjacent aesthetic device capital sales to medical practices.

5Evolus
TypeEmerging player
Description

US-focused aesthetics company marketing Jeuveau (prabotulinumtoxinA), a neurotoxin positioned as a value alternative to Botox. Competes with Bocouture and XEOMIN in the medical aesthetics channel, particularly with price-sensitive practices.

6Hugel
TypeEmerging player
Description

South Korean specialty company with Botulax (botulinum toxin type A) and a dermal filler portfolio. Increasingly competing with Merz's neurotoxin brands in Asia-Pacific and Latin America aesthetics markets.

7Allergan Aesthetics (AbbVie)
TypeDirect peer
Description

AbbVie's aesthetics division markets Botox (onabotulinumtoxinA), the global market-leading neurotoxin, plus the Juvéderm filler portfolio and CoolSculpting body-contouring devices. Direct head-to-head competitor to Merz Aesthetics' XEOMIN/Bocouture, BELOTERO and Ultherapy across both medical aesthetics and select neurology indications.

8Bausch Health (Solta Medical)
TypeBroad incumbent
Description

Through Solta Medical, Bausch markets energy-based aesthetic devices (Thermage, Fraxel, Clear+Brilliant) that compete with Merz's Ultherapy platform. Also operates the orthodermatology Salix portfolio, giving partial overlap with Merz Aesthetics' device and skincare positions.

9Sinclair Pharma
TypeDirect peer
Description

Aesthetic medicine company with hyaluronic acid fillers (MaiLi) and collagen-stimulator (Ellansé) franchises distributed through medical aesthetic practices. Directly comparable to Merz Aesthetics' filler and biostimulator portfolio across Europe and Asia.

10Ipsen
TypeDirect peer
Description

Markets Dysport (abobotulinumtoxinA) for both aesthetic and therapeutic (spasticity) indications. Directly competes with Merz's XEOMIN in neurology specialty care and Bocouture in aesthetics, with overlapping indication development in movement disorders.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Merz Pharma

Aesthetic Medicine and Pharmaceuticalsmerz.com

Merz Pharma firmographics

Firmographics
Name
Merz Pharma
Legal name
Merz Pharma GmbH & Co.KGaA
Website
https://merz.com
Company type
Private
Founded year
1908
Operating status
Operating
Headcount range
5,001–10,000 employees
Ownership category
akta.pro rank

Merz Pharma industry classification

Industry
Product category
Aesthetic Medicine and Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Perfumes, Cosmetics & Other Toilet Preparations (2844)
akta.pro primary industry
Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
akta.pro secondary industry
Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

  • Aesthetic medicine products
  • Botulinum toxin therapy
  • Dermal filler treatments
  • Neurological disorder treatments
  • Consumer healthcare products

Where Merz Pharma is headquartered

Location

Headquarters

HQ city
Deutsch
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Merz Pharma business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Distribution channels1 record

Marketing channels3 records

Merz Pharma product offering

Product offering

Core offering

Merz Pharma is a diversified healthcare company that develops, manufactures, and markets aesthetic medicine products (neurotoxins like XEOMIN/Bocouture, dermal fillers like BELOTERO, and the Ultherapy PRIME ultrasound device for non-invasive skin lifting), neurological disorder therapeutics (XEOMIN for spasticity and sialorrhea), and consumer health and wellness products (tetesept, SOS, Zirkulin, Merz Spezial, Brooklyn Soap Company) through three business units: Merz Aesthetics, Merz Therapeutics, and Merz Lifecare.

Product overview

Merz Pharma operates as a diversified healthcare company organized into three main business units: Merz Aesthetics (aesthetic medicine and skin rejuvenation products), Merz Therapeutics (neurological disorder treatments including botulinum toxin-based therapies like XEOMIN and Bocouture), and Merz Lifecare (consumer health brands including tetesept, SOS, Zirkulin, and Brooklyn Soap Company). The company also offers medical devices like Ultherapy PRIME for non-invasive skin lifting and BELOTERO dermal fillers. Founded in 1908 and headquartered in Frankfurt, Germany, Merz is a family-owned company celebrating over 110 years of operation.

Differentiator

Problem solved

Functional benefit

Brands

  • Ultherapy PRIME: FDA-cleared ultrasound treatment with real-time visualization for skin lifting
  • BELOTERO
  • XEOMIN
  • Bocouture
  • tetesept
  • SOS
  • Zirkulin
  • Merz Spezial
  • Brooklyn Soap Company

Products and services

  • Merz Aesthetics
  • Merz Therapeutics
  • Merz Lifecare
  • Ultherapy PRIME
  • BELOTERO
  • XEOMIN (incobotulinumtoxinA)
  • Bocouture

Companies that use Merz Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Merz Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Merz Pharma partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

Merz Pharma competitors and assessment

Company assessment

Direct peers

  • Galderma: Pure-play dermatology company offering Restylane and Sculptra filler franchises plus a prescription skincare portfolio. Directly comparable to Merz Aesthetics in hyaluronic acid fillers and dermatology-focused product strategy, and a key competitor in physician-dispensed aesthetics channels.
  • Allergan Aesthetics (AbbVie): AbbVie's aesthetics division markets Botox (onabotulinumtoxinA), the global market-leading neurotoxin, plus the Juvéderm filler portfolio and CoolSculpting body-contouring devices. Direct head-to-head competitor to Merz Aesthetics' XEOMIN/Bocouture, BELOTERO and Ultherapy across both medical aesthetics and select neurology indications.
  • Sinclair Pharma: Aesthetic medicine company with hyaluronic acid fillers (MaiLi) and collagen-stimulator (Ellansé) franchises distributed through medical aesthetic practices. Directly comparable to Merz Aesthetics' filler and biostimulator portfolio across Europe and Asia.
  • Ipsen: Markets Dysport (abobotulinumtoxinA) for both aesthetic and therapeutic (spasticity) indications. Directly competes with Merz's XEOMIN in neurology specialty care and Bocouture in aesthetics, with overlapping indication development in movement disorders.

Emerging players

  • Revance Therapeutics: Aesthetics and therapeutics company with the RHA dermal filler line and the DaxibotulinumtoxinA neuromodulator programme. Overlaps with Merz Aesthetics across fillers and neurotoxins and with Merz Therapeutics in neurology pipeline development.
  • Croma-Pharma: Austrian aesthetics company focused on hyaluronic acid fillers (Princess), botulinum toxin and PRP, plus ophthalmology. Overlaps with Merz Aesthetics' filler franchise and competes in similar medical-aesthetic distribution channels across Europe.
  • Cynosure / Lutronic: Aesthetic energy-based device manufacturers offering laser, RF and ultrasound platforms. Compete with Merz's Ultherapy PRIME in non-invasive skin lifting/tightening and adjacent aesthetic device capital sales to medical practices.
  • Evolus: US-focused aesthetics company marketing Jeuveau (prabotulinumtoxinA), a neurotoxin positioned as a value alternative to Botox. Competes with Bocouture and XEOMIN in the medical aesthetics channel, particularly with price-sensitive practices.
  • Hugel: South Korean specialty company with Botulax (botulinum toxin type A) and a dermal filler portfolio. Increasingly competing with Merz's neurotoxin brands in Asia-Pacific and Latin America aesthetics markets.

Broad incumbents

  • Bausch Health (Solta Medical): Through Solta Medical, Bausch markets energy-based aesthetic devices (Thermage, Fraxel, Clear+Brilliant) that compete with Merz's Ultherapy platform. Also operates the orthodermatology Salix portfolio, giving partial overlap with Merz Aesthetics' device and skincare positions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Merz Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Merz Pharma leadership team

Management profile

Number of profiles

Profiles6 records

Merz Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Merz Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Merz Pharma M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merz Pharma

What does Merz Pharma do?

Merz Pharma is a diversified healthcare company that develops, manufactures, and markets aesthetic medicine products (neurotoxins like XEOMIN/Bocouture, dermal fillers like BELOTERO, and the Ultherapy PRIME ultrasound device for non-invasive skin lifting), neurological disorder therapeutics (XEOMIN for spasticity and sialorrhea), and consumer health and wellness products (tetesept, SOS, Zirkulin, Merz Spezial, Brooklyn Soap Company) through three business units: Merz Aesthetics, Merz Therapeutics, and Merz Lifecare.

Is Merz Pharma a public or private company?

Merz Pharma is a private company. It is classified as family owned and is currently operating.

When was Merz Pharma founded?

Merz Pharma was founded in 1908. It employs 5,001 to 10,000 people.

Where is Merz Pharma based?

Merz Pharma is headquartered in Deutsch, Germany, in the Europe region.

Who are Merz Pharma's main competitors?

Direct peers on record are Galderma, Allergan Aesthetics (AbbVie), Sinclair Pharma and Ipsen. Emerging players are Revance Therapeutics, Croma-Pharma, Cynosure / Lutronic, Evolus and Hugel. Bausch Health (Solta Medical) is listed as a broad incumbent.

Does Merz Pharma have an API?

No public API is recorded for Merz Pharma.

What industry is Merz Pharma in?

Merz Pharma's product category is Aesthetic Medicine and Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FAZ.NETSupplemente: Warum der Markt mit Magnesium, Kollagen und Co. wächstA Frankfurter Allgemeine Zeitung report on the German supplement market notes that over 52 million packs were sold through German retail as of May 2026, driven by younger consumers' health concerns. It cites Merz, which marketed its "Merz Spezial Dragees" in the 1960s as the first multi-ingredient supplement, and mentions the company's new weight-loss injection.PrtimesThe Aesthetic Injectable Market is Anticipated to Surpass US$ 19.69 Billion by 2033 – PR TimesBusiness Market Insights released a market research report projecting the global Aesthetic Injectable Market to reach US$ 25.55 Billion by 2033, growing from US$ 11.34 Billion in 2025 at a CAGR of 12.3%. The report identifies the primary growth drivers as rising demand for minimally invasive cosmetic procedures, an expanding aging population, increasing social acceptance of aesthetic treatments, and rapid technological advancements in biocompatible dermal fillers and longer-lasting neuromodulators. Key players in the competitive landscape include AbbVie (Allergan Aesthetics), Galderma SA, Merz Pharma, Ipsen Pharma, Sinclair Pharma, Evolus, Revance Therapeutics, Croma-Pharma, Prollenium Medical Technologies, and Teoxane Laboratories.MerzMerz Completes Inaugural €450 Million Schuldschein Loan IssuanceMerz Group completed its first Schuldschein loan issuance, placing €450 million in the debt capital market. The transaction was oversubscribed, with proceeds settled and paid out, and included fixed- and floating-rate tranches with maturities up to ten years. The deal was arranged by BNP Paribas and DZ BANK.FortunebusinessinsightsScar Treatment Market Size, Industry ShareThe global scar treatment market was valued at USD 2.92 billion in 2025 and is projected to reach USD 7.93 billion by 2034, growing at a CAGR of 11.77% during the forecast period. Topical treatments dominate the market with approximately 65% share, while North America leads regionally at 38%, followed by Europe at 35% and Asia-Pacific at 20%. Key industry players include Smith + Nephew (12% market share) and Merz Pharma (10% market share), with growth driven by rising aesthetic awareness, demand for minimally invasive procedures, and technological advancements in laser and injectable treatments.openPR.comBotulinum Toxin Market Outlook with PR Estimates and CAGR of 6.43%, 2025-2030Data Bridge Market Research estimates the global botulinum toxin market at USD 5.81 billion in 2025, projecting growth to USD 7.93 billion by 2030 with a compound annual growth rate of 6.43%, driven by rising demand for minimally invasive aesthetic procedures, expanding therapeutic applications, and increasing adoption across emerging economies. North America holds the largest market share at approximately 40%, while Asia-Pacific is identified as the fastest-growing region, fueled by rising disposable income and medical tourism expansion. Key industry players including AbbVie Inc., Ipsen Group, Revance Therapeutics Inc., and Merz Pharma are actively driving growth through product innovations, strategic partnerships, and R&D investments in next-generation neurotoxin formulations.Straits ResearchFacial Injectable Market Size, Share, Growth, Forecast, 2034The global facial injectable market was valued at USD 10 billion in 2025 and is projected to grow to USD 20 billion by 2034, reflecting a compound annual growth rate of 8% during the forecast period (2026-2034), driven by rising preference for non-surgical procedures, anti-aging awareness, and social media influence normalizing facial rejuvenation treatments. North America dominated the market with a 46% share in 2025, while the Asia Pacific region is expected to be the fastest-growing region at a 16% CAGR. Key players in the market include Galderma, Allergan Aesthetics, Revance, Merz Pharma Gmbh, and Ipsen Pharma, who continue to drive growth through product innovation, regulatory approvals, and expanded distribution networks.openPR.comEMEA Collagenase Clostridium Histolyticum Market - Outlook 2020-2033The article discusses the market outlook for Collagenase Clostridium Histolyticum from 2020 to 2033, highlighting major companies involved in the market such as Endo International plc, Sobi, Merz Pharma, and Pfizer. It covers market trends, key drivers, opportunities, challenges, and regional analysis with Germany as the dominating region and the United Arab Emirates as the fastest-growing region.Precedence ResearchCheek Augmentation Market Size to Hit USD 6.72 Billion by 2035Precedence Research published a market analysis projecting the global cheek augmentation market to grow from USD 2.93 billion in 2025 to USD 6.72 billion by 2035, representing a CAGR of 8.64%, driven by rising aesthetic awareness, minimally invasive procedures, and advances in hyaluronic acid fillers. North America led the market with a 36% share in 2025, while Asia Pacific is expected to register the fastest growth through 2035, supported by increasing disposable income and medical tourism. The report identifies key players across the value chain including AbbVie Inc., Galderma SA, Merz Pharma, Stryker Corporation, and Zimmer Biomet, among others.PR NewswireIMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future IndustriesMultiple companies including Wintipak, Avnet, Mercury, Daimler Truck, and Merz are expanding operations or opening new facilities in Saxony-Anhalt, Germany, with key milestones scheduled for 2026. These investments involve significant capital expenditure, such as Avnet's €225 million distribution center and Merz's €50 million capacity increase, creating hundreds of new jobs. The developments highlight the region's growing attractiveness for industrial, logistics, and pharmaceutical sectors.EIN PresswireDermal Fillers and Botulinum Toxin Market Growth Outlook Across APAC, Europe, USA & Saudi Arabia Through 2035The global dermal fillers and botulinum toxin market is projected to grow from USD 6.8 billion in 2025 to USD 9.3 billion by 2035, registering a steady CAGR of 3.2%, driven by rising consumer preference for non-invasive aesthetic treatments with natural-looking results and minimal recovery time. The growth is attributed to social media influence, advancements in treatment precision, and expanding adoption across diverse age groups in regions including North America, APAC, Europe, and the Middle East. Key market players including Allergan, Galderma, Merz Pharma, and TEOXANE Laboratories are integrating AI-powered facial mapping, clinical robotics, and dynamic dosing algorithms to refine patient outcomes and reduce procedural variability.